As cell and gene therapy shifts toward in vivo approaches and regenerative modalities — iPSCs, MSCs, HSCs, and beyond — sponsors face new challenges beyond traditional CAR-T manufacturing: bioreactor and culture system selection, analytical strategy, and potency assay development for cell types with far less manufacturing precedent. Add to that the complexity of scaling from 2D to 3D culture systems, cryopreservation strategies for increasingly complex formats, and navigating regulatory pathways that are still being defined for these emerging modalities, and technical development can quickly become a bottleneck. This webinar will cover how Kincell Bio is expanding its platform to support these next-generation programs, including practical considerations for bioreactor selection, analytical and potency assay development, and regulatory strategy for early-stage sponsors. Attendees will leave with a clearer framework for planning technical development and manufacturing readiness.
In this webinar you’ll learn:
Who should attend:
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.